Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels.
As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.
Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.
Applications:Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab..
Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4℃ for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20℃.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：1mg
抗体種類：Mab
宿主：human
Source Antibody：human
Grade：Highly Purified
Purity：≥95% by reducing SDS-PAGE
Form：Supplied as a 0.2uM filtered solution, pH 6.2. No stabilizers or preservatives added.
Specificity：Recognizes human VEGF-A.
Isotype：IgG1,k
Calc Applications Abbrev：E N
Calc Crossreactivity：Hu
Immunogen：Bevacizumab biosimilar CHO stable cell line.
